Porcine models of pancreatic cancer

Katie L. Bailey, Mark A. Carlson

Research output: Contribution to journalReview article

Abstract

Pancreatic cancer is the fourth most common cause of cancer-related deaths in both men and women. The 5-year survival rate for metastatic pancreatic cancer is only 8%. There remains a need for improved early diagnosis and therapy for pancreatic cancer. Murine models are the current standard for preclinical study of pancreatic cancer. However, mice may not accurately reflect human biology because of a variety of differences between the two species. Remarkably, only 5-8% of anticancer drugs that have emerged from preclinical studies and entered clinical studies have ultimately been approved for clinical use. The cause of this poor approval rate is multi-factorial, but may in part be due to use of murine models that have limited accuracy with respect to human disease. Murine models also have limited utility in the development of diagnostic or interventional technology that require a human-sized model. So, at present, there remains a need for improved animal models of pancreatic cancer. The rationale for a porcine model of pancreatic cancer is (i) to enable development of diagnostic/therapeutic devices for which murine models have limited utility; and (ii) to have a highly predictive preclinical model in which anti-cancer therapies can be tested and optimized prior to a clinical trial. Recently, pancreatic tumors were induced in transgenic Oncopigs and porcine pancreatic ductal cells were transformed that contain oncogenic KRAS and p53-null mutations. Both techniques to induce pancreatic tumors in pigs are undergoing further refinement and expansion. The Oncopig currently is commercially available, and it is conceivable that other porcine models of pancreatic cancer may be available for general use in the near future.

Original languageEnglish (US)
Article number144
JournalFrontiers in Oncology
Volume9
Issue numberMAR
DOIs
StatePublished - Jan 1 2019

Fingerprint

Pancreatic Neoplasms
Swine
Neoplasms
Secondary Prevention
Early Diagnosis
Survival Rate
Animal Models
Clinical Trials
Technology
Equipment and Supplies
Mutation
Therapeutics
Pharmaceutical Preparations

Keywords

  • KRAS
  • P53
  • Pancreatic cancer
  • Porcine
  • Swine
  • Transgenic

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Porcine models of pancreatic cancer. / Bailey, Katie L.; Carlson, Mark A.

In: Frontiers in Oncology, Vol. 9, No. MAR, 144, 01.01.2019.

Research output: Contribution to journalReview article

Bailey, Katie L. ; Carlson, Mark A. / Porcine models of pancreatic cancer. In: Frontiers in Oncology. 2019 ; Vol. 9, No. MAR.
@article{8f74189c95744a94b568db32ba57105a,
title = "Porcine models of pancreatic cancer",
abstract = "Pancreatic cancer is the fourth most common cause of cancer-related deaths in both men and women. The 5-year survival rate for metastatic pancreatic cancer is only 8{\%}. There remains a need for improved early diagnosis and therapy for pancreatic cancer. Murine models are the current standard for preclinical study of pancreatic cancer. However, mice may not accurately reflect human biology because of a variety of differences between the two species. Remarkably, only 5-8{\%} of anticancer drugs that have emerged from preclinical studies and entered clinical studies have ultimately been approved for clinical use. The cause of this poor approval rate is multi-factorial, but may in part be due to use of murine models that have limited accuracy with respect to human disease. Murine models also have limited utility in the development of diagnostic or interventional technology that require a human-sized model. So, at present, there remains a need for improved animal models of pancreatic cancer. The rationale for a porcine model of pancreatic cancer is (i) to enable development of diagnostic/therapeutic devices for which murine models have limited utility; and (ii) to have a highly predictive preclinical model in which anti-cancer therapies can be tested and optimized prior to a clinical trial. Recently, pancreatic tumors were induced in transgenic Oncopigs and porcine pancreatic ductal cells were transformed that contain oncogenic KRAS and p53-null mutations. Both techniques to induce pancreatic tumors in pigs are undergoing further refinement and expansion. The Oncopig currently is commercially available, and it is conceivable that other porcine models of pancreatic cancer may be available for general use in the near future.",
keywords = "KRAS, P53, Pancreatic cancer, Porcine, Swine, Transgenic",
author = "Bailey, {Katie L.} and Carlson, {Mark A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fonc.2019.00144",
language = "English (US)",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Porcine models of pancreatic cancer

AU - Bailey, Katie L.

AU - Carlson, Mark A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pancreatic cancer is the fourth most common cause of cancer-related deaths in both men and women. The 5-year survival rate for metastatic pancreatic cancer is only 8%. There remains a need for improved early diagnosis and therapy for pancreatic cancer. Murine models are the current standard for preclinical study of pancreatic cancer. However, mice may not accurately reflect human biology because of a variety of differences between the two species. Remarkably, only 5-8% of anticancer drugs that have emerged from preclinical studies and entered clinical studies have ultimately been approved for clinical use. The cause of this poor approval rate is multi-factorial, but may in part be due to use of murine models that have limited accuracy with respect to human disease. Murine models also have limited utility in the development of diagnostic or interventional technology that require a human-sized model. So, at present, there remains a need for improved animal models of pancreatic cancer. The rationale for a porcine model of pancreatic cancer is (i) to enable development of diagnostic/therapeutic devices for which murine models have limited utility; and (ii) to have a highly predictive preclinical model in which anti-cancer therapies can be tested and optimized prior to a clinical trial. Recently, pancreatic tumors were induced in transgenic Oncopigs and porcine pancreatic ductal cells were transformed that contain oncogenic KRAS and p53-null mutations. Both techniques to induce pancreatic tumors in pigs are undergoing further refinement and expansion. The Oncopig currently is commercially available, and it is conceivable that other porcine models of pancreatic cancer may be available for general use in the near future.

AB - Pancreatic cancer is the fourth most common cause of cancer-related deaths in both men and women. The 5-year survival rate for metastatic pancreatic cancer is only 8%. There remains a need for improved early diagnosis and therapy for pancreatic cancer. Murine models are the current standard for preclinical study of pancreatic cancer. However, mice may not accurately reflect human biology because of a variety of differences between the two species. Remarkably, only 5-8% of anticancer drugs that have emerged from preclinical studies and entered clinical studies have ultimately been approved for clinical use. The cause of this poor approval rate is multi-factorial, but may in part be due to use of murine models that have limited accuracy with respect to human disease. Murine models also have limited utility in the development of diagnostic or interventional technology that require a human-sized model. So, at present, there remains a need for improved animal models of pancreatic cancer. The rationale for a porcine model of pancreatic cancer is (i) to enable development of diagnostic/therapeutic devices for which murine models have limited utility; and (ii) to have a highly predictive preclinical model in which anti-cancer therapies can be tested and optimized prior to a clinical trial. Recently, pancreatic tumors were induced in transgenic Oncopigs and porcine pancreatic ductal cells were transformed that contain oncogenic KRAS and p53-null mutations. Both techniques to induce pancreatic tumors in pigs are undergoing further refinement and expansion. The Oncopig currently is commercially available, and it is conceivable that other porcine models of pancreatic cancer may be available for general use in the near future.

KW - KRAS

KW - P53

KW - Pancreatic cancer

KW - Porcine

KW - Swine

KW - Transgenic

UR - http://www.scopus.com/inward/record.url?scp=85063346444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063346444&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.00144

DO - 10.3389/fonc.2019.00144

M3 - Review article

C2 - 30915276

AN - SCOPUS:85063346444

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - MAR

M1 - 144

ER -